Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. It offers tumor markers, human papilloma virus test kits, ToRCH products, Y chromosome microdeletions test kits, and multiplex immunoassay systems. The company was founded in 2003 and is based in Shanghai, China.
General Outlook
In simple terms, Tellgen Corporation has 164.206 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.585% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.196%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.189%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.079% return, is a testament to Tellgen Corporation's adeptness in optimizing resource deployment. Tellgen Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.091%. Furthermore, the proficiency of Tellgen Corporation in capital utilization is underscored by a remarkable 0.090% return on capital employed.
Stock Prices
Tellgen Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $18.85, while its low point bottomed out at $18.6. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Tellgen Corporation's stock market.
